PT  - JOURNAL ARTICLE
AU  - SHINTARO KANDA
AU  - TOMONOBU KOIZUMI
AU  - YOSHIMICHI KOMATSU
AU  - SUMIKO YOSHIKAWA
AU  - MITSUYO OKADA
AU  - ORIE HATAYAMA
AU  - MASANORI YASUO
AU  - KENJI TSUSHIMA
AU  - KAZUHISA URUSHIHATA
AU  - KEISHI KUBO
AU  - MARI SASABAYASHI
AU  - AKEMI TAKAMIZAWA
TI  - Second-line Chemotherapy of Platinum Compound plus CPT-11 Following ADOC Chemotherapy in Advanced Thymic Carcinoma: Analysis of Seven Cases
DP  - 2007 Jul 01
TA  - Anticancer Research
PG  - 3005--3008
VI  - 27
IP  - 4C
4099  - http://ar.iiarjournals.org/content/27/4C/3005.short
4100  - http://ar.iiarjournals.org/content/27/4C/3005.full
SO  - Anticancer Res2007 Jul 01; 27
AB  - Background: Optimal chemotherapeutic regimen in thymic carcinoma remains uncertain and the efficacy of second line chemotherapy has not been established either. Patients and Methods: We retrospectively evaluated the efficacy of an irinotecan plus cisplatin or carboplatin (IP) regimen as a salvage treatment for patients with unresectable thymic carcinoma that progressed after cisplatin, doxorubicin, vincristine and cyclophosphamide (ADOC) chemotherapy. Seven patients with histologically confirmed thymic carcinoma that was resistant to or who had relapsed after initial chemotherapy with ADOC were treated with IP. The treatment consisted of irinotecan (CPT-11, 60 mg/m2, days 1, 8 and 15) and cisplatin (80 mg/m2, day 1) or carboplatin (AUC 4) intravenously every 4 weeks, for at least 2 cycles. Result: Two patients achieved partial responses. Although another two patients showed a significant reduction of the primary thoracic lesion, the appearance of a new lesion was found in one and a metastatic lesion was unchanged in the other. Neutropenia over grade 3 was observed in all patients but none of the patients developed serious infections. There were no severe non-hematological toxicities, including diarrhea. Conclusion: We conclude that salvage chemotherapy may be useful in certain patients with thymic carcinoma and irinotecan may be a novel and alternative agent for relapsed thymic carcinoma.